Novartis India Limited
Novartis India Limited (NOVARTIND.NS) Stock Competitors & Peer Comparison
See (NOVARTIND.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NOVARTIND.NS | ₹1,026.30 | -0.65% | 25.4B | 26.14 | ₹39.40 | +2.42% |
| SUNPHARMA.NS | ₹1,823.50 | +2.52% | 4.3T | 39.75 | ₹45.53 | +0.91% |
| SUNPHARMA.BO | ₹1,822.40 | +2.44% | 4.3T | 39.74 | ₹45.50 | +0.91% |
| DIVISLAB.NS | ₹6,619.50 | +1.31% | 1.7T | 69.78 | ₹93.27 | +0.46% |
| DIVISLAB.BO | ₹6,618.20 | +1.27% | 1.7T | 69.52 | ₹93.25 | +0.46% |
| TORNTPHARM.NS | ₹4,251.80 | +0.48% | 1.4T | 62.63 | ₹66.93 | +0.83% |
| TORNTPHARM.BO | ₹4,252.05 | +0.52% | 1.4T | 66.12 | ₹63.25 | +0.83% |
| DRREDDY.NS | ₹1,287.20 | -3.20% | 1.1T | 19.54 | ₹67.82 | +1.21% |
| DRREDDY.BO | ₹1,287.95 | -3.17% | 1.1T | 19.50 | ₹67.84 | +1.21% |
| LUPIN.NS | ₹2,348.80 | +1.62% | 1.1T | 22.78 | ₹101.49 | +0.52% |
Stock Comparison
NOVARTIND.NS vs SUNPHARMA.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUNPHARMA.NS trades at ₹1,823.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUNPHARMA.NS's P/E ratio is 39.75. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUNPHARMA.NS's competition here
NOVARTIND.NS vs SUNPHARMA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUNPHARMA.BO trades at ₹1,822.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUNPHARMA.BO's P/E ratio is 39.74. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUNPHARMA.BO's competition here
NOVARTIND.NS vs DIVISLAB.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while DIVISLAB.NS trades at ₹6,619.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas DIVISLAB.NS's P/E ratio is 69.78. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check DIVISLAB.NS's competition here
NOVARTIND.NS vs DIVISLAB.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while DIVISLAB.BO trades at ₹6,618.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas DIVISLAB.BO's P/E ratio is 69.52. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check DIVISLAB.BO's competition here
NOVARTIND.NS vs TORNTPHARM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while TORNTPHARM.NS trades at ₹4,251.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas TORNTPHARM.NS's P/E ratio is 62.63. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check TORNTPHARM.NS's competition here
NOVARTIND.NS vs TORNTPHARM.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while TORNTPHARM.BO trades at ₹4,252.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas TORNTPHARM.BO's P/E ratio is 66.12. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check TORNTPHARM.BO's competition here
NOVARTIND.NS vs DRREDDY.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while DRREDDY.NS trades at ₹1,287.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas DRREDDY.NS's P/E ratio is 19.54. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to DRREDDY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check DRREDDY.NS's competition here
NOVARTIND.NS vs DRREDDY.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while DRREDDY.BO trades at ₹1,287.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas DRREDDY.BO's P/E ratio is 19.50. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check DRREDDY.BO's competition here
NOVARTIND.NS vs LUPIN.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while LUPIN.NS trades at ₹2,348.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas LUPIN.NS's P/E ratio is 22.78. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check LUPIN.NS's competition here
NOVARTIND.NS vs LUPIN.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while LUPIN.BO trades at ₹2,350.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas LUPIN.BO's P/E ratio is 24.46. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check LUPIN.BO's competition here
NOVARTIND.NS vs MANKIND.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, MANKIND.NS has a market cap of 926.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while MANKIND.NS trades at ₹2,257.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas MANKIND.NS's P/E ratio is 51.88. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check MANKIND.NS's competition here
NOVARTIND.NS vs MANKIND.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, MANKIND.BO has a market cap of 924B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while MANKIND.BO trades at ₹2,260.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas MANKIND.BO's P/E ratio is 51.90. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check MANKIND.BO's competition here
NOVARTIND.NS vs ZYDUSLIFE.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ZYDUSLIFE.NS has a market cap of 898.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ZYDUSLIFE.NS trades at ₹902.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ZYDUSLIFE.NS's P/E ratio is 18.21. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ZYDUSLIFE.NS's competition here
NOVARTIND.NS vs ZYDUSLIFE.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ZYDUSLIFE.BO has a market cap of 897.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ZYDUSLIFE.BO trades at ₹901.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ZYDUSLIFE.BO's P/E ratio is 18.16. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ZYDUSLIFE.BO's competition here
NOVARTIND.NS vs AUROPHARMA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AUROPHARMA.BO has a market cap of 805B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AUROPHARMA.BO trades at ₹1,375.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AUROPHARMA.BO's P/E ratio is 23.54. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AUROPHARMA.BO's competition here
NOVARTIND.NS vs AUROPHARMA.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AUROPHARMA.NS has a market cap of 804.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AUROPHARMA.NS trades at ₹1,376.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AUROPHARMA.NS's P/E ratio is 23.07. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AUROPHARMA.NS's competition here
NOVARTIND.NS vs GLENMARK.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GLENMARK.NS has a market cap of 677.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GLENMARK.NS trades at ₹2,393.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GLENMARK.NS's P/E ratio is 63.73. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GLENMARK.NS's competition here
NOVARTIND.NS vs GLENMARK.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GLENMARK.BO has a market cap of 677B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GLENMARK.BO trades at ₹2,385.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GLENMARK.BO's P/E ratio is 63.38. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GLENMARK.BO's competition here
NOVARTIND.NS vs ALKEM.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ALKEM.BO has a market cap of 649.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ALKEM.BO trades at ₹5,355.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ALKEM.BO's P/E ratio is 27.38. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ALKEM.BO's competition here
NOVARTIND.NS vs ALKEM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ALKEM.NS has a market cap of 649.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ALKEM.NS trades at ₹5,360.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ALKEM.NS's P/E ratio is 27.39. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ALKEM.NS's competition here
NOVARTIND.NS vs LAURUSLABS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, LAURUSLABS.NS has a market cap of 597.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while LAURUSLABS.NS trades at ₹1,166.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas LAURUSLABS.NS's P/E ratio is 70.79. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to LAURUSLABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check LAURUSLABS.NS's competition here
NOVARTIND.NS vs LAURUSLABS.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, LAURUSLABS.BO has a market cap of 593.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while LAURUSLABS.BO trades at ₹1,166.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas LAURUSLABS.BO's P/E ratio is 70.41. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to LAURUSLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check LAURUSLABS.BO's competition here
NOVARTIND.NS vs SUVENPHAR.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUVENPHAR.NS's competition here
NOVARTIND.NS vs SUVENPHAR.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUVENPHAR.BO's competition here
NOVARTIND.NS vs IPCALAB.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, IPCALAB.BO has a market cap of 388.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while IPCALAB.BO trades at ₹1,528.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas IPCALAB.BO's P/E ratio is 42.71. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check IPCALAB.BO's competition here
NOVARTIND.NS vs IPCALAB.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, IPCALAB.NS has a market cap of 387.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while IPCALAB.NS trades at ₹1,530.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas IPCALAB.NS's P/E ratio is 42.64. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check IPCALAB.NS's competition here
NOVARTIND.NS vs AJANTPHARM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AJANTPHARM.NS has a market cap of 353.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AJANTPHARM.NS trades at ₹2,900.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AJANTPHARM.NS's P/E ratio is 34.81. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AJANTPHARM.NS's competition here
NOVARTIND.NS vs AJANTPHARM.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AJANTPHARM.BO has a market cap of 352B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AJANTPHARM.BO trades at ₹2,904.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AJANTPHARM.BO's P/E ratio is 34.74. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to AJANTPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AJANTPHARM.BO's competition here
NOVARTIND.NS vs JBCHEPHARM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, JBCHEPHARM.NS has a market cap of 329.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while JBCHEPHARM.NS trades at ₹2,082.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas JBCHEPHARM.NS's P/E ratio is 43.24. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check JBCHEPHARM.NS's competition here
NOVARTIND.NS vs JBCHEPHARM.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, JBCHEPHARM.BO has a market cap of 328.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while JBCHEPHARM.BO trades at ₹2,080.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas JBCHEPHARM.BO's P/E ratio is 43.13. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to JBCHEPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check JBCHEPHARM.BO's competition here
NOVARTIND.NS vs EMCURE.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, EMCURE.NS has a market cap of 321.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while EMCURE.NS trades at ₹1,793.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas EMCURE.NS's P/E ratio is 36.99. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check EMCURE.NS's competition here
NOVARTIND.NS vs PEL.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check PEL.NS's competition here
NOVARTIND.NS vs WOCKPHARMA.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, WOCKPHARMA.NS has a market cap of 226.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while WOCKPHARMA.NS trades at ₹1,425.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas WOCKPHARMA.NS's P/E ratio is 1090.23. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check WOCKPHARMA.NS's competition here
NOVARTIND.NS vs WOCKPHARMA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, WOCKPHARMA.BO has a market cap of 226.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while WOCKPHARMA.BO trades at ₹1,425.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas WOCKPHARMA.BO's P/E ratio is 1089.53. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check WOCKPHARMA.BO's competition here
NOVARTIND.NS vs PPLPHARMA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, PPLPHARMA.BO has a market cap of 214.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while PPLPHARMA.BO trades at ₹160.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas PPLPHARMA.BO's P/E ratio is -65.81. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check PPLPHARMA.BO's competition here
NOVARTIND.NS vs ASTRAZEN.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ASTRAZEN.BO has a market cap of 208B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ASTRAZEN.BO trades at ₹8,046.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ASTRAZEN.BO's P/E ratio is 103.01. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to ASTRAZEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ASTRAZEN.BO's competition here
NOVARTIND.NS vs ASTRAZEN.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ASTRAZEN.NS has a market cap of 206.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ASTRAZEN.NS trades at ₹8,046.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ASTRAZEN.NS's P/E ratio is 102.17. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ASTRAZEN.NS's competition here
NOVARTIND.NS vs NATCOPHARM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, NATCOPHARM.NS has a market cap of 195.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while NATCOPHARM.NS trades at ₹1,114.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas NATCOPHARM.NS's P/E ratio is 12.58. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to NATCOPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check NATCOPHARM.NS's competition here
NOVARTIND.NS vs NATCOPHARM.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, NATCOPHARM.BO has a market cap of 195.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while NATCOPHARM.BO trades at ₹1,113.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas NATCOPHARM.BO's P/E ratio is 12.71. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to NATCOPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check NATCOPHARM.BO's competition here
NOVARTIND.NS vs NEULANDLAB.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, NEULANDLAB.NS has a market cap of 191.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while NEULANDLAB.NS trades at ₹16,124.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas NEULANDLAB.NS's P/E ratio is 106.35. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check NEULANDLAB.NS's competition here
NOVARTIND.NS vs NEULANDLAB.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, NEULANDLAB.BO has a market cap of 191B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while NEULANDLAB.BO trades at ₹16,135.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas NEULANDLAB.BO's P/E ratio is 106.25. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to NEULANDLAB.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to NEULANDLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check NEULANDLAB.BO's competition here
NOVARTIND.NS vs COHANCE.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, COHANCE.BO has a market cap of 184.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while COHANCE.BO trades at ₹469.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas COHANCE.BO's P/E ratio is 95.63. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check COHANCE.BO's competition here
NOVARTIND.NS vs COHANCE.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, COHANCE.NS has a market cap of 183.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while COHANCE.NS trades at ₹470.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas COHANCE.NS's P/E ratio is 94.63. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check COHANCE.NS's competition here
NOVARTIND.NS vs ERIS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ERIS.NS has a market cap of 183B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ERIS.NS trades at ₹1,353.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ERIS.NS's P/E ratio is 41.95. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ERIS.NS's competition here
NOVARTIND.NS vs ERIS.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ERIS.BO has a market cap of 182.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ERIS.BO trades at ₹1,354.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ERIS.BO's P/E ratio is 41.77. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ERIS.BO's competition here
NOVARTIND.NS vs GRANULES.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GRANULES.NS has a market cap of 173.7B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GRANULES.NS trades at ₹703.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GRANULES.NS's P/E ratio is 28.62. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GRANULES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GRANULES.NS's competition here
NOVARTIND.NS vs GRANULES.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GRANULES.BO has a market cap of 167.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GRANULES.BO trades at ₹703.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GRANULES.BO's P/E ratio is 30.77. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GRANULES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GRANULES.BO's competition here
NOVARTIND.NS vs APLLTD.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, APLLTD.BO has a market cap of 148.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while APLLTD.BO trades at ₹764.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas APLLTD.BO's P/E ratio is 23.49. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check APLLTD.BO's competition here
NOVARTIND.NS vs APLLTD.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, APLLTD.NS has a market cap of 148B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while APLLTD.NS trades at ₹765.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas APLLTD.NS's P/E ratio is 23.49. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check APLLTD.NS's competition here
NOVARTIND.NS vs JUBLPHARMA.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, JUBLPHARMA.NS has a market cap of 147.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while JUBLPHARMA.NS trades at ₹931.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas JUBLPHARMA.NS's P/E ratio is 34.16. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check JUBLPHARMA.NS's competition here
NOVARTIND.NS vs JUBLPHARMA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, JUBLPHARMA.BO has a market cap of 147B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while JUBLPHARMA.BO trades at ₹930.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas JUBLPHARMA.BO's P/E ratio is 34.12. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check JUBLPHARMA.BO's competition here
NOVARTIND.NS vs GLS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GLS.NS's competition here
NOVARTIND.NS vs GLS.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GLS.BO's competition here
NOVARTIND.NS vs CAPLIPOINT.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, CAPLIPOINT.BO has a market cap of 130B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while CAPLIPOINT.BO trades at ₹1,735.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas CAPLIPOINT.BO's P/E ratio is 21.24. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to CAPLIPOINT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check CAPLIPOINT.BO's competition here
NOVARTIND.NS vs CAPLIPOINT.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, CAPLIPOINT.NS has a market cap of 129.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while CAPLIPOINT.NS trades at ₹1,736.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas CAPLIPOINT.NS's P/E ratio is 21.17. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check CAPLIPOINT.NS's competition here
NOVARTIND.NS vs ALIVUS.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ALIVUS.BO has a market cap of 126B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ALIVUS.BO trades at ₹1,067.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ALIVUS.BO's P/E ratio is 23.23. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to ALIVUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ALIVUS.BO's competition here
NOVARTIND.NS vs ALIVUS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ALIVUS.NS has a market cap of 125.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ALIVUS.NS trades at ₹1,069.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ALIVUS.NS's P/E ratio is 22.44. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ALIVUS.NS's competition here
NOVARTIND.NS vs CAPPL.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check CAPPL.BO's competition here
NOVARTIND.NS vs STAR.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, STAR.BO has a market cap of 96.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while STAR.BO trades at ₹1,031.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas STAR.BO's P/E ratio is 18.82. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to STAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check STAR.BO's competition here
NOVARTIND.NS vs STAR.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, STAR.NS has a market cap of 95.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while STAR.NS trades at ₹1,031.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas STAR.NS's P/E ratio is 18.70. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check STAR.NS's competition here
NOVARTIND.NS vs VIYASH.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, VIYASH.NS has a market cap of 89.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while VIYASH.NS trades at ₹204.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas VIYASH.NS's P/E ratio is 79.10. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check VIYASH.NS's competition here
NOVARTIND.NS vs PGHL.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, PGHL.NS has a market cap of 86.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while PGHL.NS trades at ₹5,151.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas PGHL.NS's P/E ratio is 36.53. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check PGHL.NS's competition here
NOVARTIND.NS vs PGHL.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, PGHL.BO has a market cap of 85.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while PGHL.BO trades at ₹5,150.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas PGHL.BO's P/E ratio is 36.36. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check PGHL.BO's competition here
NOVARTIND.NS vs AKUMS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AKUMS.NS has a market cap of 84.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AKUMS.NS trades at ₹559.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AKUMS.NS's P/E ratio is 26.27. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to AKUMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AKUMS.NS's competition here
NOVARTIND.NS vs SUDEEPPHRM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUDEEPPHRM.NS has a market cap of 80.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUDEEPPHRM.NS trades at ₹689.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUDEEPPHRM.NS's P/E ratio is 47.68. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SUDEEPPHRM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUDEEPPHRM.NS's competition here
NOVARTIND.NS vs SHILPAMED.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SHILPAMED.NS has a market cap of 80.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SHILPAMED.NS trades at ₹418.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SHILPAMED.NS's P/E ratio is 36.28. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SHILPAMED.NS's competition here
NOVARTIND.NS vs AARTIPHARM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AARTIPHARM.NS has a market cap of 67.7B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AARTIPHARM.NS trades at ₹806.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AARTIPHARM.NS's P/E ratio is 31.73. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AARTIPHARM.NS's competition here
NOVARTIND.NS vs AARTIPHARM.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AARTIPHARM.BO has a market cap of 67.5B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AARTIPHARM.BO trades at ₹805.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AARTIPHARM.BO's P/E ratio is 31.55. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AARTIPHARM.BO's competition here
NOVARTIND.NS vs FDC.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, FDC.BO has a market cap of 60B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while FDC.BO trades at ₹372.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas FDC.BO's P/E ratio is 27.71. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to FDC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check FDC.BO's competition here
NOVARTIND.NS vs FDC.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, FDC.NS has a market cap of 59.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while FDC.NS trades at ₹371.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas FDC.NS's P/E ratio is 27.68. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check FDC.NS's competition here
NOVARTIND.NS vs SEQUENT.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SEQUENT.NS's competition here
NOVARTIND.NS vs SEQUENT.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SEQUENT.BO's competition here
NOVARTIND.NS vs SUVEN.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUVEN.BO has a market cap of 48.7B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUVEN.BO trades at ₹212.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUVEN.BO's P/E ratio is -17.06. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUVEN.BO's competition here
NOVARTIND.NS vs SUVEN.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SUVEN.NS has a market cap of 46.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SUVEN.NS trades at ₹212.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SUVEN.NS's P/E ratio is -16.99. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SUVEN.NS's competition here
NOVARTIND.NS vs SPARC.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SPARC.BO has a market cap of 46.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SPARC.BO trades at ₹139.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SPARC.BO's P/E ratio is -17.32. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SPARC.BO's competition here
NOVARTIND.NS vs SPARC.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SPARC.NS has a market cap of 46.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SPARC.NS trades at ₹139.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SPARC.NS's P/E ratio is -17.27. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SPARC.NS's competition here
NOVARTIND.NS vs INNOVACAP.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, INNOVACAP.NS has a market cap of 42.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while INNOVACAP.NS trades at ₹844.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas INNOVACAP.NS's P/E ratio is 32.38. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check INNOVACAP.NS's competition here
NOVARTIND.NS vs SHILPAMED.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SHILPAMED.BO has a market cap of 40.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SHILPAMED.BO trades at ₹418.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SHILPAMED.BO's P/E ratio is 36.25. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SHILPAMED.BO's competition here
NOVARTIND.NS vs GUJTHEM.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GUJTHEM.NS has a market cap of 39.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GUJTHEM.NS trades at ₹372.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GUJTHEM.NS's P/E ratio is 82.84. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GUJTHEM.NS's competition here
NOVARTIND.NS vs RPGLIFE.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, RPGLIFE.NS has a market cap of 38B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while RPGLIFE.NS trades at ₹2,417.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas RPGLIFE.NS's P/E ratio is 18.74. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check RPGLIFE.NS's competition here
NOVARTIND.NS vs RPGLIFE.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, RPGLIFE.BO has a market cap of 37.8B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while RPGLIFE.BO trades at ₹2,423.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas RPGLIFE.BO's P/E ratio is 18.66. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check RPGLIFE.BO's competition here
NOVARTIND.NS vs AARTIDRUGS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AARTIDRUGS.NS has a market cap of 34.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AARTIDRUGS.NS trades at ₹395.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AARTIDRUGS.NS's P/E ratio is 17.04. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AARTIDRUGS.NS's competition here
NOVARTIND.NS vs AARTIDRUGS.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, AARTIDRUGS.BO has a market cap of 34.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while AARTIDRUGS.BO trades at ₹394.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas AARTIDRUGS.BO's P/E ratio is 16.90. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check AARTIDRUGS.BO's competition here
NOVARTIND.NS vs ORCHPHARMA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ORCHPHARMA.BO trades at ₹628.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ORCHPHARMA.BO's P/E ratio is 166.71. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to ORCHPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ORCHPHARMA.BO's competition here
NOVARTIND.NS vs ORCHPHARMA.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ORCHPHARMA.NS has a market cap of 31.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ORCHPHARMA.NS trades at ₹629.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ORCHPHARMA.NS's P/E ratio is 166.12. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ORCHPHARMA.NS's competition here
NOVARTIND.NS vs BLISSGVS.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, BLISSGVS.NS has a market cap of 29.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while BLISSGVS.NS trades at ₹274.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas BLISSGVS.NS's P/E ratio is 27.13. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check BLISSGVS.NS's competition here
NOVARTIND.NS vs BLISSGVS.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, BLISSGVS.BO has a market cap of 29.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while BLISSGVS.BO trades at ₹274.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas BLISSGVS.BO's P/E ratio is 27.16. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check BLISSGVS.BO's competition here
NOVARTIND.NS vs GUFICBIO.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GUFICBIO.BO has a market cap of 28.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GUFICBIO.BO trades at ₹292.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GUFICBIO.BO's P/E ratio is 57.06. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GUFICBIO.BO's competition here
NOVARTIND.NS vs GUFICBIO.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, GUFICBIO.NS has a market cap of 28.5B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while GUFICBIO.NS trades at ₹292.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas GUFICBIO.NS's P/E ratio is 57.13. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check GUFICBIO.NS's competition here
NOVARTIND.NS vs IOLCP.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, IOLCP.NS has a market cap of 27.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while IOLCP.NS trades at ₹94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas IOLCP.NS's P/E ratio is 23.80. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check IOLCP.NS's competition here
NOVARTIND.NS vs IOLCP.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, IOLCP.BO has a market cap of 27.6B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while IOLCP.BO trades at ₹94.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas IOLCP.BO's P/E ratio is 23.80. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check IOLCP.BO's competition here
NOVARTIND.NS vs UNICHEMLAB.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, UNICHEMLAB.NS has a market cap of 27.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while UNICHEMLAB.NS trades at ₹385.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas UNICHEMLAB.NS's P/E ratio is 9.31. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check UNICHEMLAB.NS's competition here
NOVARTIND.NS vs UNICHEMLAB.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, UNICHEMLAB.BO has a market cap of 27.4B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while UNICHEMLAB.BO trades at ₹381.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas UNICHEMLAB.BO's P/E ratio is 9.30. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check UNICHEMLAB.BO's competition here
NOVARTIND.NS vs NOVARTIND.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, NOVARTIND.BO has a market cap of 25.5B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while NOVARTIND.BO trades at ₹1,021.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas NOVARTIND.BO's P/E ratio is 26.22. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check NOVARTIND.BO's competition here
NOVARTIND.NS vs SOLARA.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SOLARA.NS has a market cap of 24.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SOLARA.NS trades at ₹518.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SOLARA.NS's P/E ratio is -104.15. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SOLARA.NS's competition here
NOVARTIND.NS vs SOLARA.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, SOLARA.BO has a market cap of 24.1B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while SOLARA.BO trades at ₹518.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas SOLARA.BO's P/E ratio is -104.28. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check SOLARA.BO's competition here
NOVARTIND.NS vs ALEMBICLTD.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, ALEMBICLTD.NS has a market cap of 23.7B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while ALEMBICLTD.NS trades at ₹91.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas ALEMBICLTD.NS's P/E ratio is 7.43. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, NOVARTIND.NS is more volatile compared to ALEMBICLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVARTIND.NS.Check ALEMBICLTD.NS's competition here
NOVARTIND.NS vs HIKAL.BO Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, HIKAL.BO has a market cap of 23.3B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while HIKAL.BO trades at ₹194.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas HIKAL.BO's P/E ratio is 236.31. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to HIKAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check HIKAL.BO's competition here
NOVARTIND.NS vs HIKAL.NS Comparison May 2026
NOVARTIND.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVARTIND.NS stands at 25.4B. In comparison, HIKAL.NS has a market cap of 23.2B. Regarding current trading prices, NOVARTIND.NS is priced at ₹1,026.30, while HIKAL.NS trades at ₹194.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVARTIND.NS currently has a P/E ratio of 26.14, whereas HIKAL.NS's P/E ratio is -179.24. In terms of profitability, NOVARTIND.NS's ROE is +0.13%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, NOVARTIND.NS is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NOVARTIND.NS.Check HIKAL.NS's competition here